Eloctate (Antihemophilic factor [recombinant], Fc fusion protein) for Hemophilia

Overview
Eloctate is approved by the Food and Drug Administration (FDA) to control and prevent bleeding episodes in children and adults with factor VIII deficiency due to hemophilia A. Eloctate can also be used for perioperative (before, during, and after surgery) care and for routine prophylaxis. The technical name of Eloctate is Antihemophilic factor (recombinant), Fc fusion protein.

Eloctate is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.

How do I take it?
Prescribing information states that Eloctate is given as an intravenous injection.

Eloctate comes as a powder that must be reconstituted before injection.

Side effects
The FDA-approved label for Eloctate lists common side effects including joint pain and malaise.

Rare but serious side effects listed for Eloctate include life-threatening hypersensitivity reactions and the development of inhibitors.

For more details about this treatment, visit:

Eloctate.com

Treatment of Hemophilia – Hemophilia Federation of America